## CLAIMS:

- 1. A method for treating acute promyelogenous leukemia in a human comprising administering a therapeutically effective dosage amount of about 0.15 mg/kg arsenic trioxide once per day.
- 2. The method of claim 1, wherein said arsenic trioxide is administered until bone marrow remission, which constitutes a first administration.
- 3. The method of claim 2, further comprising a second administration of a therapeutically effective dosage amount of about 0.15 mg/kg arsenic trioxide once per day for 25 doses.
- 4. The method of claim 3, wherein said second administration is administered 3 to 6 weeks after said first administration.
- 5. The method of claim 4, wherein said second administration is administered for up to five weeks.
- 6. The method of claim 5, wherein said second administration is administered at five doses per week.
- 7. The method of claim 3, further comprising repeating said second administration.
- 8. The method of claim 7, wherein said second administration is repeated every 3 to 6 weeks.
- 9. The method of claim 8, wherein said second administration is repeated until a total of between two and ten cycles of said second administration are completed.
- 10. The method of claim 9, further comprising repeating said second administration until a total of two cycles of said second administration are completed.
- 11. The method of claim 9, further comprising repeating said second administration until a total of ten cycles of said second administration are completed.
- 12. The method of claim 1, wherein said arsenic trioxide is administered for up to sixty days, which constitutes a first administration.

- 13. The method of claim 12, further comprising a second administration of a therapeutically effective dosage amount of about 0.15 mg/kg arsenic trioxide once per day for 25 doses.
- 14. The method of claim 13, wherein said second administration is administered 3 to 6 weeks after said first administration.
- 15. The method of claim 14, wherein said second administration is administered for up to five weeks.
- 16. The method of claim 15, wherein said second administration is administered at five doses per week.
- 17. The method of claim 13, further comprising repeating said second administration.
- 18. The method of claim 17, wherein said second administration is repeated every 3 to 6 weeks.
- 19. The method of claim 18, wherein said second administration is repeated until a total of between two and ten cycles of said second administration are completed.
- 20. The method of claim 19, further comprising repeating said second administration until a total of two cycles of said second administration are completed.
- 21. The method of claim 19, further comprising repeating said second administration until a total of ten cycles of said second administration are completed.